3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
CNS
53
Sarcoma
5
Lymphoid
4
Myeloid
2
Gastrointestinal
2
Thoracic
1
Other hematologic neoplasm
1
Gynecologic
1
Genitourinary
1
Breast
1
Conditions
Breast Neoplasms
1214
Triple Negative Breast Neoplasms
216
Ovarian Neoplasms
109
Carcinoma, Non-Small-Cell Lung
85
Colorectal Neoplasms
82
Neoplasm Metastasis
78
Prostatic Neoplasms
75
Neoplasms
68
Lung Neoplasms
67
Melanoma
56
Endometrial Neoplasms
49
Stomach Neoplasms
48
Pancreatic Neoplasms
48
Uterine Cervical Neoplasms
42
Squamous Cell Carcinoma of Head and Neck
37
Colonic Neoplasms
34
Carcinoma, Intraductal, Noninfiltrating
33
Carcinoma, Renal Cell
32
Head and Neck Neoplasms
30
Sarcoma
26
Esophageal Neoplasms
25
Breast Carcinoma In Situ
24
Small Cell Lung Carcinoma
23
Brain Neoplasms
22
Urinary Bladder Neoplasms
21
Carcinoma, Transitional Cell
19
Advanced Breast Cancer
19
Anatomic Stage I Breast Cancer AJCC v8
17
Gastrointestinal Neoplasms
16
Thyroid Neoplasms
15
Interventions
trastuzumab deruxtecan
1
Temozolomide
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Astrocytoma
×
Breast
×
90 days
×
Clear all
NCT05417594
2026-06-02
CERTIS1
AstraZeneca
Phase 1/2
Recruiting
695 enrolled